UBS Group Issues Pessimistic Forecast for Pfizer (NYSE:PFE) Stock Price

Pfizer (NYSE:PFE - Get Free Report) had its price target dropped by investment analysts at UBS Group from $28.00 to $24.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a "neutral" rating on the biopharmaceutical company's stock. UBS Group's price objective indicates a potential upside of 9.65% from the company's current price.

A number of other equities analysts have also recently commented on PFE. Citigroup reiterated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. The Goldman Sachs Group reissued a "neutral" rating and issued a $25.00 price objective (down from $32.00) on shares of Pfizer in a research report on Tuesday. Finally, Truist Financial dropped their target price on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $31.07.

Pfizer Price Performance

NYSE:PFE traded up $0.30 during trading hours on Tuesday, reaching $21.89. The stock had a trading volume of 55,013,451 shares, compared to its average volume of 40,243,601. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a market capitalization of $124.14 billion, a PE ratio of 15.52, a PEG ratio of 0.64 and a beta of 0.67. Pfizer has a 52 week low of $20.92 and a 52 week high of $31.54. The company has a 50 day moving average price of $25.25 and a two-hundred day moving average price of $26.40.

Remove Ads

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the prior year, the firm earned $0.10 earnings per share. Pfizer's revenue was up 24.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Pfizer will post 2.95 earnings per share for the current fiscal year.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the firm's stock in a transaction dated Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.06% of the company's stock.

Hedge Funds Weigh In On Pfizer

Several institutional investors have recently made changes to their positions in the company. Norges Bank purchased a new position in Pfizer in the fourth quarter valued at $2,328,986,000. Charles Schwab Investment Management Inc. grew its position in shares of Pfizer by 19.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock valued at $4,124,330,000 after acquiring an additional 25,315,159 shares during the period. Starboard Value LP acquired a new position in Pfizer in the 4th quarter worth about $407,730,000. Raymond James Financial Inc. purchased a new position in Pfizer during the fourth quarter worth approximately $274,694,000. Finally, Massachusetts Financial Services Co. MA increased its position in shares of Pfizer by 7.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock valued at $2,029,604,000 after buying an additional 5,350,381 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.